Name | Title | Contact Details |
---|---|---|
Yalonda Howze |
Chief Legal Officer | Profile |
Jennifer Elliott |
Vice President, Head of Legal Affairs and Intellectual Property | Profile |
Immunocore is a privately owned British clinical-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs to treat cancer, infectious diseases and autoimmune diseases using soluble T-cell receptor technology.
Seraxis is a privately owned biotechnology company. Our GMP lab is located in Germantown, Maryland, in the heart of the vibrant BioHealth Capital Region. Launched in early 2013, Seraxis used proprietary technologies to develop a cell replacement therapy, SR-01, that is more effective and safer than embryonic stem cell-derived therapies.
Quintiles and IMSHealth have merged together to form the new QuintilesIMS. Each wanting to bring something new to customers, we deliver integrated information and technology solutions to drive healthcare forward. QuintilesIMS has approximately 50,000 employees conducting operations in more than 100 countries, dedicated to helping our clients improve their clinical, scientific and commercial results. As a global leader in protecting individual patient privacy, QuintilesIMS uses healthcare data to deliver critical, real-world disease and treatment insights.
M2GEN is an oncology-focused bioinformatics solutions company advancing precision medicine and transforming cancer care through clinical and molecular data and analytics tools. The company`s innovative dataset accelerates the discovery, development, and delivery of personalized therapies. M2GEN`s Oncology Research Information Exchange Network® (ORIEN), an alliance of NCI-Designated cancer centers that gather de-identified and lifetime-consented clinical and genomic patient data for research purposes, enables a collaborative approach to the fight against cancer for patients today and tomorrow. M2GEN currently has more than 300,000 total consented patients across a network of 18 cancer centers in 10 states.
With offices in Philadephia and Boston, SwanBio Therapeutics is developing leading-edge therapies to deliver dramatic clinical efficacy for the treatment of neurological diseases. We are driven by an unrelenting passion to solve difficult challenges, and a belief that meaningful discovery is borne of curiosity, collaboration, and compassion. Founded by proven industry leaders with a commitment to positively impacting the lives of people with neurological diseases, SwanBio merges clinical, scientific and drug commercialization expertise.